DelveInsight’s “Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Primary Biliary Cholangitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Biliary Cholangitis Market Forecast
Some of the key facts of the Primary Biliary Cholangitis Market Report:
-
The Primary Biliary Cholangitis market size was approximately ~USD 1,150 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In September 2024, Ipsen received conditional approval from the European Commission for Iqirvo® (elafibranor) 80 mg tablets, a treatment for primary biliary cholangitis (PBC) in adults who either do not respond well to ursodeoxycholic acid (UDCA) or cannot tolerate it. Iqirvo is a first-in-class oral peroxisome proliferator-activated receptor (PPAR) agonist that targets PPARα and PPARδ, which are thought to play key roles in regulating bile acid, inflammation, and fibrosis.
-
In August 2024, The FDA granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC). Livdelzi can be used alongside ursodeoxycholic acid (UDCA) in adults who do not respond adequately to UDCA, or as a monotherapy for those who are intolerant to UDCA. It is not recommended for patients with decompensated cirrhosis.
-
According to our analysis, the US reported the highest number of diagnosed prevalent cases of PBC in 2023, and these cases are anticipated to grow at a strong CAGR during the forecast period (2024–2034).
-
In 2023, Germany had the highest number of diagnosed prevalent cases of PBC among the EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, with approximately 34 thousand cases, and this number is expected to grow by 2034.
-
The incidence of PBC increases with age, peaking between 40 and 70 years. In 2023, our estimates show around 14 thousand cases in individuals under 40, with numbers rising steadily as age increases. The largest group, with 87 thousand cases, was in the 40–70 age range, while 43 thousand cases were reported in those aged 70 and above in the US.
-
Our analysis shows a higher prevalence of PBC in females than in males, with distribution rates of 82% for females and 18% for males in the US in 2023.
-
Key Primary Biliary Cholangitis Companies: CymaBay Therapeutics, Inc., Zydus Therapeutics Inc., Gannex Pharma Co., Ltd., Nanjing Chia-tai Tianqing Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, COUR Pharmaceutical, Novartis, Merck Sharp & Dohme LLC, Mirum Pharmaceuticals, Inc., Genfit, CymaBay Therapeutics, Inc., Calliditas Therapeutics, HighTide Biopharma Pty Ltd, Albireo, Curome Biosciences, Tobira Therapeutics, Inc., Pliant Therapeutics, Inc., Biotie Therapies Corp., and others
-
Key Primary Biliary Cholangitis Therapies: Seladelpar, Saroglitazar, ASC42, Obeticholic, Bezafibrate, EDP-305, CNP-104, LJN452, Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Volixibat, Elafibranor, MBX-8025, Setanaxib, HTD1801 (BUDCA), A3907, HK-660S, Cenicriviroc, PLN-74809, BTT1023, and others
-
The Primary Biliary Cholangitis epidemiology based on gender analyzed that Primary Biliary Cholangitis (PBC) is seen more among females than in males
-
The Primary Biliary Cholangitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Primary Biliary Cholangitis pipeline products will significantly revolutionize the Primary Biliary Cholangitis market dynamics.
Primary Biliary Cholangitis Overview
Primary Biliary Cholangitis (PBC), previously known as Primary Biliary Cirrhosis, is a chronic autoimmune liver disease that primarily affects the small bile ducts within the liver. Over time, these ducts become damaged and inflamed, leading to the buildup of bile (a digestive fluid) in the liver, which can subsequently cause liver damage and scarring (cirrhosis).
Get a Free sample for the Primary Biliary Cholangitis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market
Primary Biliary Cholangitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Primary Biliary Cholangitis Epidemiology Segmentation:
The Primary Biliary Cholangitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Primary Biliary Cholangitis
-
Prevalent Cases of Primary Biliary Cholangitis by severity
-
Gender-specific Prevalence of Primary Biliary Cholangitis
-
Diagnosed Cases of Episodic and Chronic Primary Biliary Cholangitis
Download the report to understand which factors are driving Primary Biliary Cholangitis epidemiology trends @ Primary Biliary Cholangitis Epidemiology Forecast
Primary Biliary Cholangitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Biliary Cholangitis market or expected to get launched during the study period. The analysis covers Primary Biliary Cholangitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Primary Biliary Cholangitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Primary Biliary Cholangitis Therapies and Key Companies
-
Seladelpar: CymaBay Therapeutics, Inc.
-
Saroglitazar: Zydus Therapeutics Inc.
-
ASC42: Gannex Pharma Co., Ltd.
-
Obeticholic: Nanjing Chia-tai Tianqing Pharma
-
Bezafibrate: Intercept Pharmaceuticals
-
EDP-305: Enanta Pharmaceuticals
-
CNP-104: COUR Pharmaceutical
-
LJN452: Novartis
-
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF): Merck Sharp & Dohme LLC
-
Volixibat: Mirum Pharmaceuticals, Inc.
-
Elafibranor: Genfit
-
MBX-8025: CymaBay Therapeutics, Inc.
-
Setanaxib: Calliditas Therapeutics
-
HTD1801 (BUDCA): HighTide Biopharma Pty Ltd
-
A3907: Albireo
-
HK-660S: Curome Biosciences
-
Cenicriviroc: Tobira Therapeutics, Inc.
-
Volixibat: Mirum Pharmaceuticals
-
PLN-74809: Pliant Therapeutics, Inc.
-
BTT1023: Biotie Therapies Corp.
Discover more about therapies set to grab major Primary Biliary Cholangitis market share @ Primary Biliary Cholangitis Treatment Landscape
Primary Biliary Cholangitis Market Drivers
-
The rise in prevalence of PBC with an increase in IBD cases, geriatric population, increase in elderly age group, and advancement in diagnostic technology such as ERCP and MBCP
-
Research and development are increasing the demand for better diagnosis and treatment options for Primary Biliary Cholangitis
Primary Biliary Cholangitis Market Barriers
-
As there is only one approved treatment for UDCAresistant Primary Biliary Cholangitis, the first drug approved in the pipeline will have a significant advantage over the others
-
The development of potential biomarkers such as miRNA for the diagnosis of Primary Biliary Cholangitis may improve the screening of Primary Biliary Cholangitis patients
Scope of the Primary Biliary Cholangitis Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Primary Biliary Cholangitis Companies: CymaBay Therapeutics, Inc., Zydus Therapeutics Inc., Gannex Pharma Co., Ltd., Nanjing Chia-tai Tianqing Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, COUR Pharmaceutical, Novartis, Merck Sharp & Dohme LLC, Mirum Pharmaceuticals, Inc., Genfit, CymaBay Therapeutics, Inc., Calliditas Therapeutics, HighTide Biopharma Pty Ltd, Albireo, Curome Biosciences, Tobira Therapeutics, Inc., Pliant Therapeutics, Inc., Biotie Therapies Corp., and others
-
Key Primary Biliary Cholangitis Therapies: Seladelpar, Saroglitazar, ASC42, Obeticholic, Bezafibrate, EDP-305, CNP-104, LJN452, Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Volixibat, Elafibranor, MBX-8025, Setanaxib, HTD1801 (BUDCA), A3907, HK-660S, Cenicriviroc, PLN-74809, BTT1023, and others
-
Primary Biliary Cholangitis Therapeutic Assessment: Primary Biliary Cholangitis current marketed and Primary Biliary Cholangitis emerging therapies
-
Primary Biliary Cholangitis Market Dynamics: Primary Biliary Cholangitis market drivers and Primary Biliary Cholangitis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Primary Biliary Cholangitis Unmet Needs, KOL’s views, Analyst’s views, Primary Biliary Cholangitis Market Access and Reimbursement
To know more about Primary Biliary Cholangitis companies working in the treatment market, visit @ Primary Biliary Cholangitis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Primary Biliary Cholangitis Market Report Introduction
2. Executive Summary for Primary Biliary Cholangitis
3. SWOT analysis of Primary Biliary Cholangitis
4. Primary Biliary Cholangitis Patient Share (%) Overview at a Glance
5. Primary Biliary Cholangitis Market Overview at a Glance
6. Primary Biliary Cholangitis Disease Background and Overview
7. Primary Biliary Cholangitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Primary Biliary Cholangitis
9. Primary Biliary Cholangitis Current Treatment and Medical Practices
10. Primary Biliary Cholangitis Unmet Needs
11. Primary Biliary Cholangitis Emerging Therapies
12. Primary Biliary Cholangitis Market Outlook
13. Country-Wise Primary Biliary Cholangitis Market Analysis (2020–2034)
14. Primary Biliary Cholangitis Market Access and Reimbursement of Therapies
15. Primary Biliary Cholangitis Market Drivers
16. Primary Biliary Cholangitis Market Barriers
17. Primary Biliary Cholangitis Appendix
18. Primary Biliary Cholangitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/